Suppression of systemic lupus erythematosus disease in mice by oral administration of kidney extract.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Suppression of systemic lupus erythematosus disease in mice by oral administration of kidney extract.

J Autoimmun. 1999 Dec;13(4):405-14. Unique Identifier : AIDSLINE MED/20054049
Ofosu-Appiah W; Sfeir G; Viti D; Burashnikova E; Department of Immunology, Masonic Medical Research Laboratory,; Utica, NY 13501, USA. ofosu@mmrl.edu

Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the increased production of antibodies reactive with a variety of self and non-self antigens. A number of immunomodulatory therapies have been investigated for the disease process. Intragastric administration of low dose kidney extract (KE) three times weekly for 5 weeks and then weekly until 6 months of age in SLE mice, showed decreased anti-dsDNA antibody levels, less kidney damage and significantly prolonged survival compared with control phosphate buffered saline (PBS)-fed mice. The KE-fed mice also exhibited reduced T cell proliferative response to KE in comparison with PBS-fed controls. Serum isotype distribution of the anti-dsDNA antibodies revealed a marked reduction of IgG1 and IgG3 responses in the KE-fed mice. While the renal inflammatory cell infiltration and expression of interleukin-4 (IL-4) and IL-10 were markedly suppressed, no local enhancement of transforming growth factor-beta (TGF-beta) was detected. Oral administration of low dose KE, however, upregulated expression of IL-2, IFN-gamma and TNF-alpha in the kidneys and suppressed glomerulonephritis. These findings suggest that oral KE affects the disease process in SLE and raise the possibility that oral administration of KE or other potential autoantigens may provide a new approach for the treatment of SLE. Copyright 1999 Academic Press.

Keywords: JOURNAL ARTICLE Administration, Oral Animal Antibodies, Antinuclear/BLOOD/IMMUNOLOGY Cytokines/BIOSYNTHESIS/GENETICS Female Glomerulonephritis/PHYSIOPATHOLOGY IgG Immune Tolerance/IMMUNOLOGY Immunoglobulin Isotypes Immunotherapy Kidney/*IMMUNOLOGY Lupus Erythematosus, Systemic/*IMMUNOLOGY/THERAPY Mice Splenomegaly/PHYSIOPATHOLOGY Support, Non-U.S. Gov't T-Lymphocytes/IMMUNOLOGY Th2 Cells/IMMUNOLOGY Tissue Extracts/THERAPEUTIC USE
000530
A0052245

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .